Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2611 to 2620 of 2683 total matches.
Tattoo Removal
The Medical Letter on Drugs and Therapeutics • Nov 24, 2003 (Issue 1170)
for tattoo removal (EL Tanzi et al, J Am Acad Dermatol 2003; 49:1). The wavelengths emitted by these lasers ...
While more people than ever are getting tattoos, many come to regret their decision and would like to have them removed. The technology of removing tattoos is much better than it used to be, but still far from perfect. Complete removal of all pigments with restoration of normal skin color and texture is not always possible (M Kuperman-Beade et al, Am J Clin Dermatol 2001; 2:21; GM Lipper and RR Anderson in IM Freedberg et al, eds, Fitzpatrick's Dermatology in General Medicine 6th ed, New York:McGraw-Hill 2003, page 2508).
Stalevo for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • May 10, 2004 (Issue 1182)
doses of levodopa/carbidopa
(100/25) plus entacapone (RA Hauser, Neurology 2004; 62 suppl 1:S64 ...
Levodopa combined with carbidopa (Sinemet, and others) is the most widely used treatment for patients with Parkinson's disease, but after 2 to 5 years most patients develop troublesome complications (Treatment Guidelines from The Medical Letter 2004; 2:41). The newest treatment for Parkinson's disease patients with end-of-dose "wearing-off" is Stalevo (Novartis), a combination of the catechol-O-methyltransferase (COMT) inhibitor entacapone (Comtan) with 3 different doses of levodopa/carbidopa. The rationale for Stalevo is that it permits some patients to take only one pill rather than...
Addendum: Dermal Fillers
The Medical Letter on Drugs and Therapeutics • Jul 16, 2007 (Issue 1265)
-mail your request to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $89; 2 years - $151 ...
Some Medical Letter consultants have suggested that our recent article on dermal fillers (Med Lett Drugs Ther 2007; 49:39) should have included stronger warnings about the risk of fillers that are not biodegradable, such as Artefill. The polymethylmethacrylate (PMMA, the same material that makes up Plexiglas) beads in Artefill can over time, even with the best technique, cause foreignbody granulomas and hypertrophic scarring, which may require surgical removal. Granulomas and nodules have been especially frequent when Artefill was injected into the lips. Complications are less likely with...
Deep Brain Stimulation for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Apr 06, 2009 (Issue 1309)
DISEASE — Medical therapy is effective for initial treatment of Parkinson’s disease.
1
Surgery should ...
Deep brain stimulation (DBS) is increasingly used to treat advanced Parkinson's disease (PD), but few controlled clinical trials have been published. New evidence from a large controlled study has recently become available.
Table: Safety of Drugs for IBD in Pregnancy (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
disease; JAK = Janus kinase; TNF = tumor necrosis factor
1. U Mahadevan et al. Gastroenterology 2019; 156 ...
View the Table: Safety of Drugs for IBD in Pregnancy
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e113 doi:10.58347/tml.2023.1680b | Show Introduction Hide Introduction
H. Influenzae Vaccine For Infants
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991 (Issue 836)
or omission. Copyright 1988-2002. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Testosterone Patches for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 24, 1996 (Issue 975)
. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Men with primary or secondary hypogonadism require lifelong androgen replacement to prevent osteoporosis and maintain normal muscle mass, erythropoiesis and sexual function (AM Matsumoto, Endocrinol Metab Clin North Am, 23:857, 1994). Until recently, the standard treatment for male hypogonadism has been an intramuscular injection of a long-acting testosterone ester every two to three weeks, which leads to serum testosterone concentrations that are high for a few days, normal for a few days more, and then may be subnormal until the next dose. Two transdermal preparations of testosterone...
In Brief: Femcon Fe: A Chewable Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Feb 26, 2007 (Issue 1255)
-mail your request to:
permissions@medicalletter.org
Subscriptions (US):
1 year - $89; 2 years - $151 ...
Femcon Fe (Warner Chilcott) is being advertised as the world's only chewable oral contraceptive. It was formerly marketed as Ovcon 35 Fe. Each packet provides 21 tablets containing 0.4 mg norethindrone and 35 mcg ethinyl estradiol, and 7 tablets with only 75 mg of ferrous fumarate. Femcon Fe has the same active hormonal ingredients as Ovcon 35 (Warner Chilcott), which has been available since 1976, and its generic equivalent Balziva (Barr); neither formulation contains iron. The spearmint-flavored Femcon Fe pill can be chewed or swallowed whole. According to the package labeling, if the pill...
Table: Mechanisms of Drug Interactions (online only)
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
methotrexate
concentrations
CYP = cytochrome P450; P-gp = P-glycoprotein
1. Drug interactions ...
View Table: Mechanisms of Drug Interactions
Ketorolac Tromethamine
The Medical Letter on Drugs and Therapeutics • Aug 24, 1990 (Issue 825)
. The Medical Letter, Inc.
Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Ketorolac (kee'; toe role ak) tromethamine (Toradol), manufactured by Syntex but also marketed by Roche, is the first parenteral nonsteroidal anti-inflammatory drug (NSAID) to become available for analgesic use in the USA. Parenteral indomethacin (Indocin I.V.) has been marketed here since 1985, but only for treatment of patent ductus arteriosus in newborn infants. Other parenteral NSAIDs are available in other parts of the world, but low potency, poor aqueous solubility, and substantial tissue irritation on injection have limited their usefulness. Ketorolac has been approved by the US ...
